Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CO NYSE:NAVB NASDAQ:VANI NASDAQ:VRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$0.95$0.99$2.03▼$5.50$115.53M0.16216,519 shs3 shsNAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shs992 shsVANIVivani Medical$1.25-6.7%$1.18$0.92▼$1.92$115.56M2.35309,379 shs242,828 shsVRMLVermillion$0.30+6.8%$3.26$0.35▼$5.78$29.21M3.47440,144 shs24,099 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood0.00%+0.05%-9.48%+0.05%-10.33%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%-66.67%VANIVivani Medical-8.09%-8.76%+15.74%-5.30%+21.36%VRMLVermillion0.00%0.00%-16.67%-34.78%+328.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$0.95$0.99$2.03▼$5.50$115.53M0.16216,519 shs3 shsNAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shs992 shsVANIVivani Medical$1.25-6.7%$1.18$0.92▼$1.92$115.56M2.35309,379 shs242,828 shsVRMLVermillion$0.30+6.8%$3.26$0.35▼$5.78$29.21M3.47440,144 shs24,099 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood0.00%+0.05%-9.48%+0.05%-10.33%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%-66.67%VANIVivani Medical-8.09%-8.76%+15.74%-5.30%+21.36%VRMLVermillion0.00%0.00%-16.67%-34.78%+328.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGlobal Cord Blood 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/AVANIVivani Medical 2.00Hold$3.50180.00% UpsideVRMLVermillion 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VRML, NAVB, VANI, and CO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2026VANIVivani Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.50(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGlobal Cord Blood$1.24B0.09$0.23 per share4.19$6.34 per share0.15NAVBNavidea Biopharmaceuticals$8.13K0.00N/AN/AN/ANaNVANIVivani MedicalN/AN/AN/AN/A$0.20 per shareN/AVRMLVermillion$4.54M6.43N/AN/A$0.09 per share3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGlobal Cord Blood$79.04M$0.641.49N/AN/AN/AN/AN/AN/ANAVBNavidea Biopharmaceuticals-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/AVANIVivani Medical-$26.61M-$0.43N/AN/AN/AN/A-317.03%-82.64%5/12/2026 (Estimated)VRMLVermillion-$15.24MN/AN/AN/AN/A-307.31%-155.25%-103.47%N/ALatest VRML, NAVB, VANI, and CO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026VANIVivani Medical-$0.08N/AN/AN/AN/AN/A3/26/2026Q4 2025VANIVivani Medical-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGlobal Cord Blood$0.088.42%N/A12.50%N/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AVRMLVermillionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGlobal Cord BloodN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AVANIVivani MedicalN/A2.712.71VRMLVermillion0.202.512.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGlobal Cord BloodN/ANAVBNavidea Biopharmaceuticals0.01%VANIVivani Medical6.78%VRMLVermillion18.09%Insider OwnershipCompanyInsider OwnershipCOGlobal Cord Blood0.50%NAVBNavidea Biopharmaceuticals43.68%VANIVivani Medical46.40%VRMLVermillion4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionNo DataVANIVivani Medical2086.24 million46.22 millionOptionableVRMLVermillion4397.38 millionN/ANot OptionableVRML, NAVB, VANI, and CO HeadlinesRecent News About These CompaniesVermillion authorities investigate car vs building crashAugust 10, 2024 | keloland.comKVermillion, SD Hourly Weather ForecastApril 30, 2024 | wunderground.comWVermillion named Tree City USAApril 21, 2024 | siouxcityjournal.comSVermillion girls' basketball rallies to win Class A state titleMarch 13, 2024 | siouxcityjournal.comSPeoria police thwart school shooting; teen could be charged as an adultFebruary 18, 2024 | pjstar.comP2023 HW Vanguard: Dale VermillionOctober 15, 2023 | housingwire.comHGoodwill coming to VermillionSeptember 17, 2023 | siouxcityjournal.comSIn Telangana, Vermillion And Saffron Threads Were Used To Lure Women VotersSeptember 2, 2023 | outlookindia.comVermillion, SD 10-Day Weather ForecastJuly 17, 2023 | wunderground.comWA cold case without a crime: Inside the messy investigation into two missing SD teens in 1971June 21, 2023 | grandforksherald.comGCamellia VermillionJune 16, 2023 | health.usnews.comDr. Richard L. KnutsonJune 6, 2023 | health.usnews.comVermillion Elementary SchoolMay 24, 2023 | usnews.comDr. Kenneth J. VermillionMay 20, 2023 | health.usnews.comGolf: Vermillion Runner-Up At Huskies Invitational | Sports | plaintalk ... - Vermillion Plain TalkMay 13, 2023 | news.google.comNDriver killed after veering into path of dump truck on Highway 52 - Bring Me The NewsMay 13, 2023 | news.google.comNFatal crash in Vermillion Township closes portion of Highway 52 - CBS NewsMay 13, 2023 | news.google.comNVermillion, KS Weather ConditionsMay 13, 2023 | wunderground.comWVermillion Softball Falls To Tea Area 12-2 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNBaseball: Dakota Valley Blanks Vermillion 7-0 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026A Quiet Outperformer With a Catastrophe CaveatBy Peter Frank | April 14, 2026Could Easing Iran Tensions Trigger an Amazon Pre-Earnings Rally?By Sam Quirke | April 6, 20263 Overlooked Nuclear Fuel Supply Chain WinnersBy Nathan Reiff | April 26, 2026VRML, NAVB, VANI, and CO Company DescriptionsGlobal Cord Blood NYSE:CO$0.95 0.00 (0.00%) As of 05/4/2026Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Navidea Biopharmaceuticals NYSE:NAVBNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Vivani Medical NASDAQ:VANI$1.25 -0.09 (-6.72%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.24 -0.01 (-0.48%) As of 05/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Vermillion NASDAQ:VRMLVermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
